Endo A, Kuroda M, Tsujita Y (1976). “ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum”. J Antibiot29 (12): 1346-1348. PMID 1010803.
Tsujita Y, Kuroda M, Tanzawa K, Kitano N, Endo A (1979). “Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase”. Atherosclerosis32 (3): 307-313. PMID 223590.
Kuroda M, Tsujita Y, Tanzawa K, Endo A (1979). “Hypolipidemic effects in monkeys of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase”. Lipids14 (6): 585-589. PMID 110993.
The Lovastatin Study Group II (1986). “Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study”. JAMA256 (20): 2829-2834. PMID 3534333.
Grundy SM (1988). “HMG-CoA reductase inhibitors for treatment of hypercholesterolemia”. NEJM319 (1): 24-33. PMID 3288867.
Christians U, Jacobsen W, Floren LC (1998). “Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?”. Pharmacol Ther80 (1): 1-34. PMID 9804052.
Ma PT, Gil G, Südhof TC, Bilheimer DW, Goldstein JL, Brown MS (1986). “Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits”. Proc Natl Acad Sci USA83 (21): 8370–8374. PMID 3464957.
